Backgound: The growing availability of active agents makes the development of novel therapies increasingly complex and the choice of end points critical. We assessed the frequency of use of efficacy end points in advanced breast cancer.
introduction
Over the past 15 years, significant advances have been achieved in the systemic treatment of advanced breast cancer. Foremost among these advances have been the introduction of novel chemotherapeutic agents [1] , the use of aromatase inhibitors in postmenopausal women [2, 3] , and of trastuzumab in patients with HER-2-overexpressing tumors [4, 5] . In addition, promising novel therapies in advanced breast cancer include the antiangiogenic mAb bevacizumab [6] , the tyrosinekinase inhibitor lapatinib [7] , and the epothilone ixabepilone [8] .
The growing availability of active agents against advanced breast cancer makes clinical development of novel therapies increasingly more complex. In addition to the growth in the number of possible drugs and combinations to be tested, and the possibility of testing novel therapies in different treatment lines, the choice of end points to be used in clinical trials is becoming a critical issue in drug development. Given its objectivity and the unquestionable benefit derived by patients, overall survival (OS) has been historically considered the most important end point in advanced breast cancer [9] . However, patient survival may be influenced by therapies used after participation in a given trial, and some randomized trials are actually underpowered to detect OS differences [10] . As a matter of fact, OS gain has only occasionally been achieved in the hundreds of randomized trials conducted to date in advanced breast cancer [9] .
Progression-free survival (PFS) is defined as the time elapsed between treatment initiation and tumor progression or death from any cause, with censoring of patients who are lost to follow-up [11] . Many recent trials have used PFS or time to tumor progression (TTP) as the primary end points, with TTP theoretically differing from PFS in that the event of interest is only disease progression [12, 13] . Both PFS and TTP have traditionally been considered as surrogate end points for OS, as far as the drug approval process is concerned [14, 15] . Given the key role played by the choice of end points for clinical trials and for drug approval, we assessed the recent literature on advanced breast cancer regarding the use of efficacy end points in randomized trials, with the specific aim of quantifying the frequency of their use. 
data abstraction and analysis
We abstracted from the full articles relevant data for analysis, with the goal of describing the extent to which the most important time-dependent efficacy end points (PFS, TTP, and OS), as well as response rate (RR), had been used in the recent literature. For each study, we obtained the primary and two secondary efficacy end points following authors' definitions in the paper; when the hierarchy of end points had not been clearly stated in the article, we ranked them in the order in which they were cited in the 'Methods' or 'Results' section of the paper. We also collected data on less common end points, such as duration of response, time to treatment failure (TTF), complete RR, and time to proven drug resistance [18] . The number of patients was the number of patients who were eligible for efficacy analyses, and the number of patients per arm was the latter divided by the number of arms (except for one study with a 2 : 1 randomization [19] ). For studies in which the intent-to-treat (ITT) population was used for the primary analyses (or when the results of the ITT population were reported first, in the case of studies not specifying which was the primary analysis), the number of ITT patients was considered as the number of patients in the trial. We assessed the frequency and the consistence of the definition of PFS and TTP reported in the Methods or Results section of the articles. We abstracted the median follow-up for the PFS/TTP analyses when a separate follow-up was reported for the survival analyses. We also carried out exploratory analyses by comparing studies that were grouped according to specific characteristics. Means of normally distributed variables were compared with Student's t-test, and the chi-square test was used for comparing proportions.
results characteristics of the studies use of end points in advanced breast cancer
As shown in Figure 1 , the primary end points most frequently used were RR and TTP (n = 21 each), followed by PFS (n = 14), TTF, and OS (n = 1 each). RR was also the most common secondary end point overall (n = 31), followed by OS (n = 30), and duration of response (n = 25). When only the 39 first-line trials were considered (green bars in Figure 1 ), RR and TTP were again the most frequent primary end points (n = 14 each), followed by PFS (n = 9), OS, and TTF (n = 1 each). For the 39 trials published in the Journal of Clinical Oncology, TTP and RR were the most frequently used primary end points (n = 14 each), followed by PFS (n = 10), and TTF (n = 1). When chemotherapy-only trials were analyzed, RR was used in 16 cases, TTP in 10, PFS in nine, and OS was used once as a primary end point. Dividing the 58 trials according to the year of publication, 29 were published between 2000 and 2003 
definitions of end points
In five of the 21 trials using TTP as the primary end point, no definition of this end point was reported in the article. Analysis of the other 16 cases showed that progressive disease was always considered an event in TTP analysis. However, in 13 (81.3%) of these cases, death (either from breast cancer or from any cause) was also counted as an event. The definition of PFS was reported in the article in 13 of the 14 trials using this primary end point. In all cases, the events of interest in Kaplan-Meier analyses included both progressive disease and death. In the only study using TTF as the primary end point, TTF was defined as the time from randomization until progression, relapse, or death from any cause. Of note, only one trial used both PFS and TTP as efficacy end points; for this trial, the definition of TTP differed from that of PFS in considering only deaths from breast cancer, whereas PFS included death from any cause as an event.
comparison between groups of studies Given the similarities between PFS, TTP, and TTF, and the fact that these end points have been used with equivalent intent in many trials, we grouped the studies that had one of these as the primary end points (n = 36) and compared them with those using RR as the primary end point (n = 21). As shown in Table 2 , there were no significant differences between those two groups of trials in the parameters chosen for comparison. However, trials using RR as the primary end point had a smaller mean number of patients than trials that used PFS, TTP, or TTF (P = 0.061).
discussion
Our review of the literature suggests that PFS and TTP considered together are the primary end points most frequently used in randomized trials in advanced breast cancer. RR is another frequently used primary end point, whereas OS has been used in only 1 of 58 clinical trials. Our study also suggests that PFS and TTP have been used interchangeably by investigators.
The chief limitation of our study is the fact that we only looked at articles appearing within an 8-year period in one of eight selected medical journals, reasoning that these journals published most of the randomized clinical trials in advanced breast cancer. Although we have no reason to believe that such selection criteria have introduced bias in our analysis, it is conceivable that the assessment of articles published in other journals would lead to different conclusions, especially with regard to the frequency of use of primary end points and other quantitative issues relating to time-dependent end points. On the other hand, we believe our finding of the lack of consistency of the definition of TTP is noteworthy, independent of the adequacy with which the sample analyzed in our study is representative of randomized clinical trials in breast cancer in general. A second consideration regarding the limitations of our study is the fact that its design does not allow the assessment of publication bias. It is possible that negative studies, which would eventually stand a lower chance of being published, have used efficacy end points in different proportions than their positive counterparts. Also, the consistency of the definition of TTP may have been different in unpublished studies, when compared with published trials.
Methodological issues on end points have attracted considerable interest lately, especially in the fields of breast and colorectal cancer [13, 20, 21] . Members of the Standardized Definitions for Efficacy End Points in Adjuvant Breast Cancer Trials (STEEP) group have pointed out that there is a lack of consistency in the definitions of many efficacy end points and that those definitions should be standardized to facilitate accurate communication among investigators, clinicians, regulatory agencies, funding agencies, clinicians, and patients, as well as exploratory cross-study comparisons [20] . The goal of that group is therefore to increase the quality of adjuvant breast cancer clinical trial conduct and reporting, while reducing the chances for miscommunication and misunderstanding on matters of interpretation of efficacy results from trials. That goal will hopefully be achieved through the proposal of specific definitions on end points to be used in clinical trials on the adjuvant treatment of breast cancer. Similar initiatives have been undertaken in colorectal cancer, both in the adjuvant [21] and in the metastatic disease settings [13] . To our knowledge, no similar proposals have been put forward to date regarding advanced breast cancer.
There has been a growing debate on the appropriateness of using OS as an end point in clinical trials in oncology. Such debate has been ongoing in the case of advanced colorectal cancer for several years [10, 12, 22, 23] . In colorectal cancer, OS Figure 1 . Use of efficacy end points in randomized clinical trials in advanced breast cancer (only one primary and up to two secondary end points were collected from each trial; for three trials, there was only one secondary end point). The percentage for each bar color represents the frequency of the end point in that particular situation (blue bars represent primary end points overall; red bars represent secondary end points overall; green bars represent primary end points in the first line). Each bar color adds up to 100%. CRR, complete response rate; DOR, duration of response; OS, overall survival; PFS, progression-free survival; resist, time to proven resistance to tamoxifen [18] ; RR, response rate; TTF, time to treatment failure; TTP, time to tumor progression.
original article Annals of Oncology is considered by some as a flawed efficacy criterion since potentially active subsequent therapies are not controlled in many randomized trials, and measured OS may be increased or decreased by such therapies [22] . Evidently, the same reasoning may be applied in advanced breast cancer, given the existence of several effective lines of therapy [24] and the lack of control over treatments administered in subsequent lines. Although not looking specifically for this, we found only one study in our series in which second-line therapy was part of the protocol in all study arms [25] . Furthermore, in both advanced colorectal and breast cancer, many recently reported trials lacked power to detect a statistically significant increase in survival, even in the presence of other benefits [10] .
Taken collectively, our study suggests that PFS and TTP have been used as primary end points in 60% of recent randomized trials in advanced breast cancer. Both PFS and TTP have historically been considered as surrogate end points for OS, at least from the standpoint of drug approval [14, 15] and notwithstanding the controversy surrounding their formal validation in breast cancer [24, [26] [27] [28] . According to the Food and Drug Administration (FDA), PFS may be preferable to TTP as a correlate of OS because it is able to capture fatal toxicity in trials where the majority of deaths are expected to be related to cancer [29] . Perhaps the most notable finding from our study is the high frequency with which the definition of TTP included death as an event and not as reason for censuring. In some studies, the terms TTP and PFS have even been used interchangeably within the same trial [30, 31] . In the trial that used both PFS and TTP as efficacy end points, the definition of TTP considered only deaths from breast cancer, whereas that of PFS included death from any cause as an event [7] .
TTF is usually defined as the time elapsed between treatment initiation and tumor progression, treatment discontinuation due to toxicity, patient preference, or death [11, 14] . A similar definition was used in some of the trials included in our review. However, in the only trial in our review using TTF as the primary end point, TTF was defined as the time from the date of randomization until the date of disease progression, relapse, or death from any cause without documented progression or relapse (i.e. a definition typically used for PFS) [32] . Such definition of TTF has also been used when this was a secondary end point [33] . Because TTF in its original definition is a composite end point that also includes symptom assessment, it is rarely accepted by the FDA in drug approval [14] .
RR has been used as the primary efficacy end point in approximately one-third of the randomized trials included in our review. This is an interesting finding, given the known limitations of response assessment as an indicator of treatment benefit in oncology [34] . Exploratory analyses suggested that trials using RR as the primary end point tend to be smaller in size than those using PFS, TTP, and TTF. On the other hand, treatment type and setting, as well as journal and year of publication, did not appear to discriminate between these two main choices in end points.
In our study, we were surprised to find that the median follow-up was available for only 48% of trials, a proportion relatively similar to that reported recently by MathoulinPelissier et al. [35] , who found that the median follow-up was expressed in the results section for only 57% of 125 articles on various tumor types and treatment settings.
In conclusion, PFS and TTP seem to be the primary end points most frequently used in contemporary randomized trials in advanced breast cancer. However, PFS and TTP have often been used interchangeably. The lack of uniformity regarding the definition of end points may lead to miscommunication and to confusion when results of different trials are compared, and uniform adoption of the definitions seems therefore in order. 
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